Difference between revisions of "Aripiprazole LA-Aripiprazole"
From Psychiatrienet
| Line 4: | Line 4: | ||
| stop = {{Lastinjection}} | | stop = {{Lastinjection}} | ||
| start = {{Startslweeks}} | | start = {{Startslweeks}} | ||
| − | | info = {{ | + | | info = {{SPCaripiprazoleLA}} |
| view = StopDepotStartOral.jpg | | view = StopDepotStartOral.jpg | ||
}} | }} | ||
Latest revision as of 16:53, 16 March 2015
| ||||||||||||||||||||||||||
| ||||||||||||||||||||||||||
Switch medication from Aripiprazole LA to Aripiprazole.[1] [2]
Stop Aripiprazole LA - Day 1: Last depot injection
Start Aripiprazole- Week 1-3: approx. 25% of target dose
- Week 4-6: approx. 50% of target dose
- Week 7-9: approx. 75% of target dose
- Week 10: target dose
More information- More information you'll find in the summary of product characteristics (SPC) of aripiprazole depot injection. [3]
— Aripiprazole LA — Aripiprazole
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002755/WC500156111.pdf SPC of the European Medicines Agency on aripiprazole depot
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
